ArticleEuropean journal of neurology2023

Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study.

Fabrizio Vernieri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.